Whether invasive mucinous adenocarcinoma (IMA) and colloid adenocarcinoma (ICA) of the lung represent separate tumour entities, or simply lie within a spectrum of phenotypic variability, is worth investigating. Fifteen ICA, 12 IMA, 9 ALK-rearranged adenocarcinomas (ALKA), 8 non-mucinous KRAS-mutated adenocarcinomas (KRASA) and 9 mucinous breast adenocarcinomas (MBA) were assessed by immunohistochemistry for alveolar (TTF1, cytoplasmic MUC1), intestinal (CDX-2, MUC2), gastric (membrane MUC1, MUC6), bronchial (MUC5AC), mesenchymal (vimentin), neuroendocrine (chromogranin A, synaptophysin), sex steroid hormonerelated (oestrogen and progesterone receptors), pan-mucinous (HNF4A) and pan-epithelial (keratin 7) lineage biomarkers and by targeted next generation sequencing (TNGS) for 50 recurrently altered cancer genes. Unsupervised clustering analysis using molecular features identified cluster 1 (IMA and ICA), cluster 2 (ALKA and KRASA) and cluster 3 (MBA) (p < 0.0001). Cluster 1 showed four histology-independent sub-clusters (S1 to S4) pooled by HFN4A and MUC5AC but diversely reacting for TTF1, MUC1, MUC2, MUC6 and CDX2. Subcluster S1 predominantly featured intestinal-alveolar, S2 gastrointestinal, S3 gastric and S4 alveolar differentiation. In turn, KRASA and ALKA shared alveolar lineage alongside residual MUC5AC expression, with additional focal CDX2 and diffuse vimentin, respectively. A proximal-to-distal scheme extending from terminal (TB) and respiratory (RB) bronchioles to alveolar cells was devised, where S3 originated from distal TB (cellular mucinous adenocarcinoma), S2 from proximal RB (secreting mucinous adenocarcinoma), S1 from intermediate RB (mucin lake-forming colloid adenocarcinoma), S4 from distal RB (colloid alveolar adenocarcinoma), KRASA from juxta-alveolar RB (KRAS-mutated non-mucinous adenocarcinoma) and ALKA from juxta-bronchial alveolar cells (ALK-translocated adenocarcinoma). TNGS analysis showed KRAS, LKB1, TP53, APC and CDKN2A mutation predominance. In conclusion, IMA and ICA are basket categories, which likely originate from distinct domains of stem/progenitor cells spatially distributed along bronchioles upon common molecular features and genetic alterations.
Introduction
Among mucin-laden adenocarcinomas (MLA) of the lung, the 2015 WHO classification identifies mucinous adenocarcinoma in situ, minimally invasive mucinous adenocarcinoma, invasive mucinous adenocarcinoma (IMA) and invasive colloid adenocarcinoma (ICA) [1] . Invasive enteric adenocarcinoma (IEA) resembling the homologous intestinal tumours has been included as a variant [1] . Other MLA types are solid adenocarcinoma with mucin [1] and signet ring cell adenocarcinoma (SRCA) [2] , although SRCA has been downgraded to mere cytological change of any pattern's adenocarcinoma [1] . Lastly, there are nonmucinous adenocarcinomas accumulating extracellular mucin, which have been reappraised as histological patterns of adenocarcinoma with mucin extravasation (HPAME) [3] . IMA, ICA and IEA share many phenotypic traits, which are opposed to conventional nonmucinous adenocarcinomas and HPAME. Expression of NK2 homeobox 1/thyroid-specific transcription factor-1 (NKX2-1/TTF-1) [4] [5] [6] [7] , napsin A aspartic peptidase (NAPSA) [4, 8, 9] , surfactant protein A1 (SFTPA1) [5, 8] , caudal type homeobox 2 (CDX2) [5, 6, 8, 10, 11] , keratin 20 (KRT20) [5, 6, 8, 12] , mucin 1 cell surface associated (MUC1) [13] , mucin 2 oligomeric mucus/gel-forming (MUC2) [5, 11, 13] , mucin 5AC oligomeric mucus/gel-forming (MUC5AC) [5, 10, 13] , mucin 6 oligomeric mucus/gel-forming (MUC6) [10, 13, 14] and hepatocyte nuclear factor 4 alpha (HFN4A) [15] , have been variably reported onto emphasize the inherent heterogeneity of these tumours. Furthermore, IMA may even express neuroendocrine (NE) markers [16] and sex steroid hormone receptors [17, 18] .The molecular landscape of IMA, ICA, IEA and, to lesser extent, HPAME is dominated by KRAS [3, 6, 10, 19, 20] , TP53 and LKB1/STK11 [21, 22] over Epidermal Growth Factor Receptor (EGFR) mutations [3, 6, 19] , while the CD74-NRG1 fusion genes has been documented in 13-27% KRAS-wild type tumours [23, 24] . Most SRCA harbour ALK rearrangement [2, 25] .
Recent data have indicated that synchronous KRAS mutation and Nkx2-1/TTF1 repression cause IMA in the lung [26] , with napsin-A downregulation [10] and gastric over intestinal differentiation [10, 27] . These Nkx2-1/TTF1-deleted IMA with KRAS mutation grew in well-differentiated multiple foci upon reduced apoptosis from mucinous precursors in the distal bronchiole epithelium [27] , developing metastases only when loss-of-function TP53 mutation occurred [28] .
According to these assumptions, it is tempting to speculate that IMA, ICA and IEA lie with in a spectrum of relatively uniform tumours on molecular grounds [6, 19, 20, 23] , which differ upon morphology and immunohistochemistry (IHC) traits [4] [5] [6] [7] [8] 10] . They would therefore embody prototypical lesions resembling gastro-entero-pancreatic or gynaecological tumours [29] [30] [31] [32] , and even primary ALK-translocated adenocarcinoma (ALKA) when abundant extracellular mucin is accumulated [6, 11, 33, 34] . Upon IHC and molecular investigation, we herein suggest that IMA, ICA and IEA make up a heterogeneous family of tumours encompassing four different subgroups, which likely arise from different cancer progenitor/ stem cell niches in the distal airways.
Materials and methods

Study design
We designed and conducted a proof-of-concept study to challenge whether pulmonary IMA, ICA and IEA encompass separate tumour entities with distinct phenotypic profiles depending upon varying interplay of architectural complexity and lineage changes (cellular phase) or mucin production and extravasation (secretion phase), under the pooling of a common mucinencoding gene activation programme, or simply made up a spectrum of histological heterogeneity.
Patients and tumours
A series of 44 consecutive resection specimens of mucin-laden lung adenocarcinoma patients from 25 males averaging 63.8 years (range 28-85 years) and 19 females averaging 61.4 years (range 38-80) were retrospectively identified in the pathology archives of the participant Institutions among diagnoses of lung adenocarcinoma, inasmuch as ICA, IMA and ALKA are less likely to be documented in surgical specimens for being either quite uncommon tumours or inoperable lesions in most instances at the time of the clinical diagnosis. All tumours fulfilling diagnostic criteria for mucin-laden adenocarcinoma made up different comparable groups in terms of confounding factors, such as age, gender and tumour stage as detailed in supplementary material A. They included 15 ICA (5 pure and 10 mixed with non-colloid component), 12 IMA (9 pure and 3 mixed with nonmucinous component), 9 ALKA and 8 non-mucinous KRAS-mutated adenocarcinomas (KRASA). The occurrence of ALK rearrangement and KRAS mutation had been verified by fluorescence in situ hybridization [35, 36] and Sanger direct sequencing of exon 2 to 4 [37, 38] , respectively. As negative control 
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A Sonzogni et al group of non-pulmonary and unrelated MLA, nine mucinous breast adenocarcinomas (MBA) entered the study, inasmuch as mucin-laden adenocarcinomas of the lung are prototypical lesions with similarities to homologous digestive and gynaecological mucinous tumours likely due to commonalities in the embryological derivation and pathogenesis. All tumours were classified according to the criteria of WHO classifications on lung [1] and breast [39] cancer. There were 30 specimens from (bi)-lobectomy, 12 from segmentectomy and 2 from pneumonectomy corresponding to 21 tumours staged IA, 5 staged IB, 2 staged IIA, 11 staged IIB, 3 staged IIIA and 1 staged IV (one patient was lost to pathologic staging). Information on smoking habit was not available at the time of the present study and survival analysis was not a specific endpoint of the study. All surgical specimens had been fixed in 4% buffered formaldehyde solution for 12-24 hr and embedded in paraffin according to standard histopathological methods. All the original haematoxylin and eosin sections were jointly reviewed by four (GP, MC, AF, AS) of the authors for consistency, without knowledge of the patients' identities or original tumour categorization. Pleural invasion was classified as PL0, PL1, PL2 and PL3 according to updated criteria [40] .
The group of IMA, ICA, ALKA and KRASA was comparatively studied for age, gender, type of surgery, tumour stage, tumour diameter, number of excised lymph nodes, percentage of metastatic lymph nodes, pT factor, pN factor, pleural invasion, architectural patterns and variants, and occurrence of signet ring, goblet or floating cells (each by 10% cutoff for presence vs. absence), extracellular mucin (cutoff 50% for minor vs. prevalent) and type of mucin (basophilic, amphophilic or both), as detailed in supplementary material A.
In particular, non-mucinous adenocarcinoma components were expressed as percentages of patterns of growth and variants in 5% numerical increments according to current classification guidelines [1] . No cases of adenocarcinoma in situ or minimally invasive adenocarcinoma were documented in this study.
Immunohistochemistry
The primary antibody list entering the study and technical information on IHC procedures is available in supplementary material B and supplementary material C, respectively. The antibodies included biomarkers of alveolar (TTF-1, MUC1), gastrointestinal (CDX-2, keratin 20, MUC2, MUC6), bronchial (MUC5AC), NE (chromogranin A, synaptophysin), mesenchymal (vimentin), sex steroid hormone (oestrogen and progesterone receptors), pan-mucinous (HNF4A) and pan-epithelial (keratin 7) differentiation lineages, along with the ALK rearrangementassociated protein. Normal lung tissue was investigated for the same IHC biomarkers.
Molecular study
The group of IMA/ICA/IEA tumours underwent targeted-next generation sequencing (NGS). Normal lung tissue was used as negative controls as appropriate for consistency. Detailed descriptions of the molecular procedures pursued in this investigation, including DNA extraction, quantification and targeted next generation sequencing (TNGS) analysis, have been reported previously [35, 37, 38] . In brief, NGS analysis was carried out using small DNA samples (10 ng/ll) from tumour paraffin sections accounting for at least 80% cellularity, with the Ion AmpliSeq Cancer Hotspot Panel v.2 (Life Technologies-Thermo Fisher Scientific, Waltham, MA, USA) running on the Ion-Torrent TM Personal Genome Machine platform comprising 50 oncogenes and tumour suppressor genes recurrently mutated in human cancers (Life Technologies-Thermo Fisher Scientific), as previously detailed [37, 38] .
Ethics
The study was approved by the independent ethics committee of the National Tumour Institute IRCCS Foundation, Milan, Italy (accession number INT-188/15). All patients gave their written consent for diagnosis and research activities when they were admitted to the hospital.
Statistics
Statistical analyses were performed using JMP IN software (SAS Institute, Inc., Cary, NC) and VassarStats for Statistical Computation at http://vassarstats. net website. Qualitative or quantitative data were compared by Fisher exact t test, chi-squared test, Mann-Whitney test and Kruskal-Wallis test as appropriate. Unsupervised and supervised hierarchical clustering analyses were performed using Cluster 3.0 software (http://www.eisenlab.org/eisen/) and visualized using Java TreeView (http://jtreeview.sourceforge.net). The defining features of the diverse clusters corresponded to the different IHC percentages used for the relevant markers. Similarity was measured using Spearman rank correlation metric and clustering was performed by centroid linkage. Contingency analysis and relative mosaic plots were performed by means of JMP IN software and 
Results
Analysis by histology
We initially searched for either morphology or relevant IHC findings, which stratified the cohort of 44 lung adenocarcinomas. In KRASA and IMA, we found only predominant acinar-cribriform or solid with mucin and lepidic/acinar/enteric patterns, respectively, and basophilic mucin in IMA, while in ICA, ALKA and KRASA we found the presence of extracellular mucin and SRC and the lack of goblet and freely floating cells, respectively (supplementary material A).The IHC analysis revealed that the alveolar biomarkers prevailed in mixed IMA/ICA, ALKA and KRASA, whereas gastrointestinal biomarkers were preferentially expressed in IMA and ICA along- 
Analysis by clustering
We then used hierarchical clustering analysis to perform a molecular classification of this cohort of 53 MLA, using a set of known IHC biomarkers. Such analysis revealed three main clusters and a nonrandom distribution of these IHC biomarkers across the 53 MLA under evaluation. Upon histology, cluster 1 included a mixture of IMA and ICA and, unexpectedly, even one KRASA case; cluster 2 comprised all ALKA and the remaining KRASA cases; cluster 3 was limited to MBA (p < 0.0001) ( Figure 1A and 1B). Upon IHC, gastrointestinal (CDX-2, keratin 20, membrane MUC1, MUC6), bronchial (MUC5AC) and pan-mucinous (HNF4A) biomarkers prevailed in cluster 1, whilst alveolar (TTF1, cytoplasmic MUC1), ALKA-related (ALK protein, vimentin) and sex steroid hormone along with MUC2 were dominant in clusters 2 and 3, respectively. The remaining biomarkers were not differentially distributed, even though NE biomarkers prevailed in the cluster 3 (Table 1) .
Analysis by sub-clustering
Next, we further characterized the composition of cluster 1, which revealed the presence of four distinct sub-clusters, named S1 to S4 (Figure 2 ). Upon histology, a mixture of colloid and mucinous/non-mucinous patterns was seen in S4, mucinous pattern in S2 and S3 and colloid variant in S1. Moreover, floating cells with amphophilic extracellular mucin clustered in S1 only (supplementary material E; supplementary material, Figure S2 ).Upon IHC, differential distribution was found among sub-clusters for TTF1, MUC1, CDX-2, MUC2, MUC6 andHNF4A but no other biomarkers, which were thus excluded from further analysis (supplementary material F). Of note, MUC1 labelled cell membranes in sub-cluster 3, while was confined to cytoplasm in sub-clusters S1, S2 and S4, as in the normal lung tissue (Table 2 ; supplementary material F). The six biomarkers were then used for reclassifying IMA and ICA, regardless of histology. According to the distribution of alveolar and gastrointestinal biomarkers, S3 and S4 sub-clusters were placed at both ends and S1 and S2 sub-clusters in the middle of a physio-anatomical unit extending from bronchioles up to alveolar cells (supplementary material, Figure S3 ). Briefly, sub-cluster S3 featured exclusive gastric differentiation (membrane MUC1, MUC6), S2 admixed gastric and intestinal lineage, S1 admixed intestinal and alveolar biomarkers and S4 escalation of alveolar traits with striking downregulation of intestinal biomarkers (Table 2) . Pan-mucinous HNF4A tracer significantly decreased from S3/S2/S1 to S4 sub-cluster, whereas MUC1-reactiveextracellular mucin accumulation increased from S3/S2 sub-clusters (4/11 cases, 36.4%) to S1/S4 sub-clusters (14/17 cases, 82.4%) ( Table 2) 
Analysis by TNGS
Finally, we performed next-generation sequencing of the same cohort of tumours to further look at the genetic alterations underpinning the different histological subtypes and molecular sub-clusters. There were 22 mutated out of 28 analysed tumours (78%) totalling 32 mutations (1.45 mutation/tumour patient). The most frequent mutation turned out KRAS (16 cases) followed by LKB1 (4 cases), TP53 (4 cases), APC (2 cases), CDKN2A (2 cases) and HFN1A, c-KIT, SMAD4 and SMO in 1 case each, regardless of histology (supplementary material, Figure S10 ). There were no preferential types of KRAS mutation. The rate for any mutation was 50% (2/4)in S3, 57% (4/7) in S2, 54% (7/13) in S1, 100% (4/4) in S4 and 100% (7/7) in KRASA (p 5 0.021) (supplementary material F). No differences emerged between trans-versions (17/32 mutations) and transitions (15/32 mutations), irrespective of genes. ALKA were not subjected to TNGS analysis.
Discussion
In our study, we noticed that the visceral endoderm HFN4A master gene in Nkx2-1/TTF1-downregulating and KRAS-mutated tumours [10, 26, 41] could be placed at the top of a developmental scheme (Figure 3) , where HFN4A acted as inducer of mucinous differentiation via MUC5AC trans-activation [26, 41, 42] . MUC5AC was in turn significantly lower than HNF4A [41] , while is normally limited to bronchiolar goblet cells. The lack of recognizable precursor lesions (bronchial columnar cell dysplasia [43] or mucinogenic growth clusters [44, 45] ), suggested that alternative non-linear or de novo mechanisms were likely to play some role in tumour development since the reported genotypic and phenotypic profile of these precursors [44, 45] adapted to only a subset of lesions in our study. The subsequent tumour evolution depended on the relative activation state of Nkx2-1/TTF1, which basically causes mucin repression in terminal respiratory unit cells [26, 46] . The inverse relationship of HNF4A with Nkx2-1/TTF1 and its direct correlation with CDX-2 [47] and MUC6 were likely to induce either mucinous gastric differentiation of antral gland/mucopeptic cell type Table 2 . Histogenetic analysis by immunohistochemistry and stratification by sub-clusters S1 to S4 [10, 26, 48] or secretory intestinal lineage [49] . CDX-2 in turn closely associated to MUC2 expression [50] and, marginally, was alternative to Nkx2-1/TTF1, in keeping with the finding of TTF1 and CDX-2 coexpression even at the level of individual tumour cells. Depolarized MUC1 decoration we documented in varying proportions has been linked to cell detachment [51] , apoptosis impairment [52] and cancer cell proliferation [53] . This peculiar and non-random distribution of master regulators and activation products made us hypothesize that diversely regulated niches or domains of mucinous-committed stem/progenitor cancer cells existed in bronchioles, in keeping with lung ontogenesis, as suggested by the congeries of tumours in cluster 1. These tumours recapitulated two alternative biological properties: increasing architectural complexity (cellular phase) and mucin escalation (secretion phase), both phenomena being under the control of common genetic traits. When the cellular phase predominated, multifocal tumours with more advanced stage developed, which featured antral gland/foveolar gastric (membrane MUC1, MUC6) and/or intestinal (CDX-2, MU2) but nil or negligible alveolar (TTF1, cytoplasmic MUC1) cell lineage. When gastric differentiation prevailed upon complete TTF1 silencing (S3 sub-cluster), there were multiple microscopic neoplastic foci of welldifferentiated and organoid cells with membrane MUC1-related cell detachment, lepidic growth, tufting, stromal invasion and spread through air spaces. These cells preserved the secretion polarity and Figure 3 . Operative flow-chart showing the development of lung adenocarcinomas with mucin production from different stem/reserve cell niches distributed along the terminal and respiratory bronchioles up to alveolar cells. A new terminology was then devised on the basis of differential phenotypic combinations of the S1 ! S4 sub-clusters of cluster 1 and cluster 2 tumours. Profiles were considered negative if staining was completely absent in the relevant cells; focally (6) immunoreactive cases exhibited immunostaining in 1-10% neoplastic cells; 1 cases in 11-50% neoplastic cells; 11 cases in 50% or more neoplastic cells. The prefix 'juxta' stands for 'near to'.
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A Sonzogni et al exhibited basophilic mucin, negligible extravasation and uncommon freely floating elements. When combined gastrointestinal trans-differentiation occurred (S2 sub-cluster) upon HNF4A-induced CDX-2 and MUC2 activation [50, 54] while persisting Nkx2-1/ TTF1 downregulation, multiple microscopic neoplastic foci of less differentiated tumour cells developed alongside a greater architectural complexity revealed by incipient enteric features, less preserved secretion polarity, amphophilic mucin extravasation and freely floating tumour cells. Mitoses and apoptotic bodies were undetectable in S3 but not enteric foci of S2 sub-cluster, indicating that apoptosis blockage [27] and cell proliferation diversely accounted for the growth of these tumours (data not shown). S3 and S2 sub-clusters were strikingly homologous to the gastric and pancreatobiliary subtypes of intra-ductal papillary mucinous neoplasms (IPMN) of the pancreas, respectively, inasmuch as the gastric subtype is often multifocal and the pancreatobiliary subtype shows CDX2 expression [55] , in keeping also with a common embryologic origin from the foregut. When the secretion phase predominated, massforming and localized tumours developed with either an exorbitant and grossly appreciable extracellular mucin pouring or microscopic mucin remnants encasing mucinous epithelium. If intestinal differentiation prevailed upon HNF4A-induced CDX-2 upregulation (S1 sub- cluster), there were MUC1-positive amphophilic mucin lakes encasing freely floating elements, less architectural complexity, colloid-type stromal dissection and negligible tumour cell proliferation if not in less differentiated enteric foci (data not shown).These tumours sometimes co-expressed CDX-2 and TTF1 at the level of individual cells. This developmental scheme was strikingly similar to the intestinal subtype of pancreatic IPMN, which usually forms large cystic lesions involving the main duct [55] . If alveolar differentiation prevailed (S4 sub-cluster), mass-forming lung-type tumours were encountered with solid appearance, less differentiated enteric foci and MUC1-positive amphophilic mucin remnants encasing freely floating elements. NE cell component was virtually limited to these two sub-clusters only intestinal differentiation as hallmarked by garland-like architecture, eosinophilic cytoplasm, terminal bars and dirty necrosis crossed S1, S2, S4 but not S3 sub-cluster. These observations would suggest that IEA are phenotypic changes only in lung IMA and ICA in keeping with current defining criteria [1] , which are likely to be related to pancreatic rather than colorectal cancer [56] . Overall, we organized our results stepwise according to six different categories as highlighted in Figure 4 (MBA were excluded because they were completely unrelated tumours).
S3 sub-cluster tumours showed gastric-type differentiation [16] and more advanced stage likely related to impaired apoptosis. These tumours were thought to derive from distal terminal bronchioles and termed cellular mucinous adenocarcinoma.
S2 sub-cluster tumours maintained antral glandtype MUC6 as seen in incomplete intestinal metaplasia [57] , whilst CDX-2 recruitment alongside negligible Nkx2-1/TTF1 activity caused a more complete intestinal differentiation to appear [58] in less differentiated and more advanced tumours. This tumour category was thought to derive from proximal respiratory bronchioles and was termed secreting mucinous adenocarcinoma. S1 sub-cluster tumours showed predominance of secreting intestinal (CDX-2/MUC2) differentiation responsible for inverted secretion polarity with freely floating cells, simplified architecture and less advanced tumours. These tumours were thought to derive from intermediate respiratory bronchioles and were termed mucin lake-forming colloid adenocarcinoma.
S4 sub-cluster tumours showed overwhelming alveolar lineage recruitment, with minor mucin secretion, less floating cells and less advanced tumour stage, mucinous epithelium or enteric features were seen. These tumours were thought to derive from distal respiratory bronchioles and were termed colloid alveolar adenocarcinoma.
Non-mucinous KRASA featured Nkx2-1/TTF1 and MUC1 expression [59] , while repressed any secreting gastro-enteric lineage [26, 27] . These KRASA with poor secretion were thought to derive from the most distal or juxta-alveolar region of the respiratory bronchiole and were termed KRAS-mutated non-mucinous adenocarcinoma.
ALK-translocated tumours silenced intestinal-type mucinous differentiation and activated depolarized MUC1-depending cell disaggregation and vimentinrelated epithelial-mesenchymal transition vimentin accumulation via Nkx2-1/TTF1 and oncogenic ALK recruitment, respectively [59] [60] [61] . These tumours were thought to derive from proximal, juxtabronchial progenitors of alveolar structures and were simply defined as ALK-translocated adenocarcinoma.
No synchronous or metachronous metastatic tumours were available for analysis in terms of intertumour heterogeneity, but the relative homogeneity of sub-clusters we observed made marked differences in genotypic or phenotypic traits quite unlikely to occur in this tumour setting. The figure of 79% for any identified gene mutation was in keeping with the literature [3, 6, 15, 19, 20] , but studies on CD74-NRG1 fusion of KRAS-negative tumours have been planned. Limitations of this the study were the relatively small number in each tumour category and the lack of validation sets, yet these lung tumours are in absolute terms quite rare and ALKA, KRASA and MBA were indeed validation control groups. The lack of survival analysis and the use of targeted NGS rather than whole exome/transcriptome analysis may have limited drawing definite conclusions. However, strength points were the identification of interpretative biomarkers in accordance with normal lung tissue distribution, multiple and non-random significant differences across the diverse tumour categories, a close genotype-phenotype relationship in the relevant tumour categories and coherence of results with current concepts on the development of MLA and tissue-specific adult stem cells in human lung [62] .
Conclusion
Despite improvements in lung cancer classification, IMA, ICA, IEA and, to some extent, ALKA and non-mucinous KRASA continue to blur with each other for concurrent unanswered phenomena. In this scenario, six IHC biomarkers and simple molecular findings allowed an effective reappraisal of IMA, ICA, IEA, ALKA and non-mucinous KRASA according to spatially organized and histology-independent tumour categories. Supplementary material E. Clinico-pathological data by unsupervised sub-clustering S1 to S4
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Supplementary material F. Immunohistochemistry and molecular data by unsupervised sub-clustering S1 to S4
Supplementary figure legends Figure S1 . Distribution of TTF1, MUC5AC, MUC1 and HNF4A in normal lung tissue Figure S2 . Relationship between sub-clusters S1 ! S4 and TTF1, MUC1, CDX-2, MUC2 and MUC6 immunostaining Figure S3 . Relationship between sub-clusters S1 ! S4 as defined by immunohistochemistry findings and histological classification of mucinous and colloid adenocarcinoma, either pure or mixed Figure S4 . Mucin lake-forming colloid adenocarcinoma (sub-cluster S1) Figure S5 . Secreting mucinous adenocarcinoma (sub-cluster S2) Figure S6 . Cellular mucinous adenocarcinoma (sub-cluster S3) Figure S7 . Alveolar colloid adenocarcinoma (sub-cluster S4) Figure S8 . Non mucinous KRAS-mutated adenocarcinoma Figure S9 . ALK-rearranged adenocarcinoma 
